Literature DB >> 27018505

Development and validation of a stability-indicating RP-HPL C-CAD method for gabapentin and its related impurities in presence of degradation products.

Pramod Kumar Ragham1, Kothapalli B Chandrasekhar2.   

Abstract

The objective of the current study was to develop and validate a sensitive and specific LC-MS compatible stability indicating reversed phase liquid chromatographic method for the quantitative determination of Gabapentin and its related substances using Corona charged aerosol detection (CAD). The chromatographic conditions were optimized using a Kinetix Biphenyl column with gradient elution using a mobile phase composed of pH 4.2 ammonium acetate, acetonitrile, and methanol. Forced degradation was observed in basic and peroxide conditions and the major degradants were identified by LC-MS/MS analysis. The developed RP-HPLC CAD method was validated according to ICH guidelines. The LOD and LOQ values for Gabapentin and all its related impurities ranged from 0.075μg/mL to 0.18μg/mL and 0.25μg/mL to 0.60μg/mL, respectively. The recovery for all impurities ranged from 91.0 to 105.6%w/w. Solutions were stable for 7days at room temperature. The validated method produced acceptable precision, linearity, accuracy, robustness and ruggedness.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corona charged aerosol detector (CAD); Forced degradation; Gabapentin; Related substances; Stability-indicating assay

Mesh:

Substances:

Year:  2016        PMID: 27018505     DOI: 10.1016/j.jpba.2016.03.035

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Development and Validation of a Chromatography Method Using Tandem UV/Charged Aerosol Detector for Simultaneous Determination of Amlodipine Besylate and Olmesartan Medoxomil: Application to Drug-Excipient Compatibility Study.

Authors:  Ariadne M Brondi; Jerusa S Garcia; Marcello G Trevisan
Journal:  J Anal Methods Chem       Date:  2017-12-17       Impact factor: 2.193

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.